Shi Liu, Liu Yang, Yang Zhengmeng, Wu Tianyi, Lo Hiu Tung, Xu Jia, Zhang Jiajun, Lin Weiping, Zhang Jinfang, Feng Lu, Li Gang
Department of Orthopaedics & Traumatology, Faculty of Medicine, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, NT, People's Republic of China.
Department of Orthopaedics, School of Medicine, Zhongda Hospital, Southeast University, No. 87 Ding Jia Qiao, Nanjing, 210009, Jiangsu, People's Republic of China.
Calcif Tissue Int. 2021 Jul;109(1):55-65. doi: 10.1007/s00223-021-00820-9. Epub 2021 May 17.
Vasoactive intestinal peptide (VIP) as a neuromodulator and neurotransmitter played a significant role in modulating bone homeostasis. Our previous study reported an essential role of VIP in in vitro BMSCs osteogenesis and in vivo bone defect repair. VIP was also revealed to have a promoting effect on embryonic skeletal element development. However, the role of VIP in fracture healing is not known yet. We hypothesized that the disorder of sympathetic nervous system impairs bone structure and fracture healing, whereas VIP may rescue the sympathetic inhibition effects and promote fracture healing. We employed a 6-hydroxydopamine (6-OHDA) induced sympathectomy mice model (sympathectomized mice), in which successful sympathetic inhibition was confirmed by a decreased level of norephedrine (NE) in the spleen. In the sympathectomized mice, the femoral micro-architecture, bone density and mechanical properties were all impaired compared to the vehicle control mice. The femoral fracture was created in the vehicle or sympathectomized mice. Vehicle mice were locally injected with PBS as a negative control, and the sympathectomized mice were treated with injection of PBS or VIP. VIP expression at the fracture site was significantly decreased in sympathectomized mice. The fracture healing was repressed upon 6-OHDA treatment and rescued by VIP treatment. Micro-CT examination showed that the femoral bone micro-architecture at the fracture sites and mechanical properties were all impaired. Simultaneously, the expression level of osteogenic markers OCN and OPN were reduced in sympathectomized mice compared with vehicle group. While the VIP treatment rescued the repression effects of 6-OHDA on bone remodeling and significantly promoted bone quality and mechanical properties as well as increased osteogenesis marker expression in the sympathectomized mice. VIP administration promoted bone fracture healing by inhibiting bone resorption, making it a putative new alternative treatment strategy for fracture healing.
血管活性肠肽(VIP)作为一种神经调节剂和神经递质,在调节骨稳态中发挥着重要作用。我们之前的研究报道了VIP在体外骨髓间充质干细胞成骨和体内骨缺损修复中的重要作用。VIP还被发现对胚胎骨骼元素发育有促进作用。然而,VIP在骨折愈合中的作用尚不清楚。我们假设交感神经系统紊乱会损害骨结构和骨折愈合,而VIP可能会挽救交感神经抑制作用并促进骨折愈合。我们采用6-羟基多巴胺(6-OHDA)诱导的交感神经切除术小鼠模型(去交感神经小鼠),通过脾脏中去甲麻黄碱(NE)水平降低证实了成功的交感神经抑制。与载体对照小鼠相比,去交感神经小鼠的股骨微观结构、骨密度和力学性能均受损。在载体或去交感神经小鼠中制造股骨骨折。载体小鼠局部注射PBS作为阴性对照,去交感神经小鼠注射PBS或VIP进行治疗。去交感神经小鼠骨折部位的VIP表达显著降低。6-OHDA处理会抑制骨折愈合,而VIP处理可挽救这种抑制作用。显微CT检查显示骨折部位的股骨骨微观结构和力学性能均受损。同时,与载体组相比,去交感神经小鼠中成骨标志物骨钙素(OCN)和骨桥蛋白(OPN)的表达水平降低。而VIP处理挽救了6-OHDA对骨重塑的抑制作用,显著促进了去交感神经小鼠的骨质量和力学性能,并增加了成骨标志物的表达。VIP给药通过抑制骨吸收促进骨折愈合,使其成为一种潜在的骨折愈合新替代治疗策略。